Small Molecule Approaches to the Management of Macular Degeneration by Short-Circuiting the Visual Cycle

Summary Age related macular degeneration (AMD) affects millions of persons worldwide and is a leading cause of vision loss and blindness in ageing populations. In this disease, daytime vision (cone dominated vision) degrades with time because cone photoreceptors, which are concentrated in the foveal region of the retina, die. The incidence of this disease increases from less than 10% of the population 50 years of age to over 30% at 75 and continues upwards past this age.

Dr. Robert Rando at Harvard Medical School has identified a number of small molecules that target a new point in the visual cycle. Some molecules have been shown to bind to the target in the 40pM range in vitro. Inhibition of this target should delay or prevent progression of macular degeneration.

Harvard has applied for patents for this invention.

Applications Age related macular degeneration vision ophthamology For Further Information Please Contact the Director of Business Development Michal Preminger Email: [email protected] Telephone: (617) 432-0920

Inventor(s): Rando, Robert R

Type of Offer: Licensing



Next Patent »
« More Pharmaceutical Patents
« More Medical Patents

Share on      


CrowdSell Your Patent